

## Agenda

STP Bay Area Regional Meeting Dec 6, 2019			
Agenda			
Time	Speaker	Affiliation	Topic
8.30-8:55 AM	NA	NA	Registration/ Coffee
8.55-9:00 AM	Steven Laing BVMS(Hons) PhD DACVP	Genentech	Introduction
9:00-9:50 AM	Denise Imai DVM PhD DACVP	Comparative Pathology Lab, UC Davis	Phenotyping Strategies for the Knock Out Mouse Project
9:50-10:40 AM	Sara Santagostino DVM PhD DACVP	Genentech	The role of GEMM in Safety Assessment
10:40-11:00 AM	COFFEE BREAK		
11:00-11:50 AM	Wendy Halpern DVM PhD DACVP	Genentech	Assessment of Antibody Dependent Enhancement of Disease in a Flu Model
12:00-1:00 PM	LUNCH		
1.00 1:50 PM	James Turk DVM PhD DACVP	Amgen	Morphological and Transcriptional Endpoints in Apolipoprotein-E Knockout Mouse Models of Atheroprogession: Examination of Plausible Mechanisms of Cardiovascular Adverse Events
1:50-2:40 PM	Lauri Diehl DVM PhD DACVP	Gilead	Interpretation of mouse models of IBD
2:40-3:00 PM	COFFEE BREAK		
3.00-3:50 PM	Artem Skhumatov DVM PhD DACVP	Amgen	Comparative Pathology and Interpretation of Mouse Models of NASH
4.00 PM	SOCIAL	All	
5.00 PM	CLOSE		

### **Lauri J. Diehl, DVM, PhD, DACVP**

Lauri J. Diehl is currently Executive Director, Research Pathology at Gilead Sciences. She obtained her BS (1986) and DVM (1998) from Kansas State University and completed an Anatomic Pathology Residency/PhD in 1995 at Colorado State University, studying feline retroviral disease with Dr. Ed Hoover. She completed a Postdoctoral fellowship in 1998, at Stanford University focusing on HIV subtypes in clinical trials and studied a murine model of rotavirus infection. She became a Diplomate of the American College of Veterinary Pathologists in 2001. She was a Research Pathologist at Deltagen from 2000 to 2002 and Principal Pathologist, Research Pathology at Genentech from 2002 to 2018. Dr. Diehl is an active participant in the American College of Veterinary Pathologists where she is the Annual Meeting Chair for 2019 and was previously the Education Chair (2018), Education Committee Focused Scientific Session Chair (2015-2016), Career Development session chair (2016), Education Committee Awards Chair (2013-2014), Concurrent Session chair (2014), and Experimental Disease Committee member (2004-2007; committee chair, 2006). Dr. Diehl is also a Scientist reviewer for Department of Defense Peer Reviewed Medical Research Program grants (IBD and Gastrointestinal Disease sections, 2015-present), has been a member of the STP Scientific Program committee (2011-2015), STP scientific symposium IBD chair (2013), STP membership committee (2012-2015), and is an Ad hoc reviewer for Nature, Journal of Pathology, Toxicologic Pathology, Inflammatory Bowel Diseases, Physiologic Genomics, and Veterinary Pathology.

### **Wendy Green Halpern, DVM, MSc, PhD, DACVP**

Wendy Green Halpern received her DVM (1992) and a MSc in Veterinary Pathology (1994) from The Ohio State University, then completed her PhD training in Biomedical Sciences at the University of New Mexico Health Sciences Center in 1999. After a brief postdoctoral fellowship, Dr. Halpern began a 20-year career in the Biotechnology Industry, first at Human Genome Sciences in Rockville MD, then in the Genentech Safety Assessment Pathology group in South San Francisco CA, where she is currently a Principal Scientist-Pathologist. Over her career, she has supported the development of many antibody and protein therapeutics across a broad range of oncology, infectious diseases, cardiovascular, metabolic, immunology and rheumatology targets and indications. Dr. Halpern has been an active member of the STP since 2005. She has served on the Scientific and Regulatory Policy Committee, and is a current member of the Annual Symposium Committee. Other professional activities include membership on the BioSafe Leadership Committee since 2014, and BIO representative on the ICH S11 Working Group since 2015. She is a member of the Safety Pharmacology Society, the Teratology Society and the HESI DART Technical Committee, reflecting personal interests in safety pharmacology, reproductive pathology, and support of pediatric drug development. She has published book chapters and manuscripts across a number of topics relevant to toxicologic pathology and biopharmaceutical drug development.

### **James R. Turk, DVM, PhD, DACVP**

James R. Turk, completed a BA in Biology at Washington University, St. Louis, MO; DVM at the University of Missouri in Columbia, MO; PhD at Washington State University, and Pathology Residency at Washington Animal Disease Diagnostic Laboratory in Pullman, WA. He is certified in anatomic pathology by the American College of Veterinary Pathologists. Jim was Assistant and Associate Professor at Louisiana State University, Baton Rouge, LA; and is Professor Emeritus of Biomedical Sciences and Pathology, University of Missouri Columbia. Jim has won numerous awards for teaching professional and graduate students, including 2 Norden Awards for Distinguished Teaching in Veterinary Medicine, performed many years of diagnostic service, and award-winning research in cardiovascular disease funded by the National Heart Lung and Blood Institute. Jim has worked as a Pathologist at Merck in Westpoint, PA, and Pfizer, St. Louis, MO, and since 2008 has been a Pathology Director at Amgen, Thousand, Oaks, CA in the Department of Comparative Biology and Safety Sciences. He is currently Functional Group Lead: Translational Cardiovascular Pathology and Biomarkers in the Safety Pharmacology and Animal Research Center.

### **Artem Shkumatov, DVM, PhD, DACVP**

Dr Artem Shkumatov is a principal pathologist at Amgen in South San Francisco. Dr. Shkumatov received his DVM in 1998 from the Vitebsk Veterinary Academy in Belarus. After practicing veterinary medicine for two years, he accepted a research appointment at the Center for Transgenic Animals of the Institute for Molecular Genetics in Moscow, Russia, where he worked on creation of several transgenic mouse models and studied spontaneous and directed differentiation in embryonic stem (ES) cells. In 2002, Dr. Shkumatov accepted a position as a research embryologist at the Reproductive Genetics Institute in Chicago, Illinois, focusing on *in vitro* embryo culture, chromosomal pathology and mosaicism in pre-implantation embryos resulting in early embryonic lethality. Dr. Shkumatov returned to academia in 2008 to complete the combined residency/PhD program in veterinary anatomic pathology at the University of Illinois at Urbana-Champaign. He is a Diplomate of the American College of Veterinary Pathologists (2011) and finalized his dissertation focusing on how matrix rigidity impacts cellular differentiation and function in ES cell derived cardiovascular organoids and revascularization in a model of critical limb ischemia via stem cell transplantations in 2014. Dr. Shkumatov has been a member of the STP since 2012.

### **Denise M. Imai-Leonard, DVM, PhD, DACVP**

Dr. Denise M. Imai-Leonard is Director of the Comparative Pathology Laboratory (CPL) and Health Sciences Associate Clinical Professor in the Department of Pathology, Microbiology and Immunology, at the School of Veterinary Medicine, UC Davis. She obtained her DVM (2004) and completed specialty training, both at UC Davis, becoming board-certified in Anatomic Pathology in 2007. She completed a PhD in 2013 in Comparative Pathology at UC Davis, with her dissertation focusing on host-pathogen interactions in the mouse model of chronic Lyme borreliosis, under the mentorship of Dr. Stephen Barthold. Currently, she manages a high-throughput laboratory animal diagnostic facility that provides health surveillance, clinical

diagnostics and pre-clinical research pathology support for the University of California system and private industry clients. She is co-coordinator for the UC Davis Laboratory Animal Pathology Residency/Fellowship, coordinator for the bi-monthly Laboratory Animal Pathology Rounds webinar between CPL, CNPRC and Stanford University, After-live/Pathology coordinator for the UC Davis Knockout Mouse Project in the Davis, Toronto, Charles River and CHORI consortium, co-chair of the Test Item Writers Group and Histopathology chair for the Exam Administration and Assembly Group (formerly ACVP Examination Committee).

**Sara F. Santagostino, DVM, PhD, DACVP**

Dr. Santagostino is a board-certified veterinary pathologist working in the Department of Safety Assessment at Genentech since 2017. She received her veterinary medical degree and PhD from the University of Milan, Italy, and completed her veterinary pathology residency training at the University of Pennsylvania. She joined the Safety Assessment pathology group at Genentech following a fellowship in Comparative and Genomic Pathology at Memorial Sloan Kettering Cancer Center in New York. Sara supports the nonclinical safety evaluation of both small and large molecules intended for several therapeutic areas including immunology, oncology, and neuroscience. Her expertise includes the pathobiology of laboratory animals used in biomedical research and drug development with emphasis on the phenotyping of genetically engineered animal models for the detection of potential safety liabilities. Externally, Sara is an active member and co-chair of the ACVP Experimental Disease Focused Scientific Group.